Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Abeona’s Global Sanfilippo Syndrome Trial Gains Ground In Spain

By Mike Botta | November 10, 2017

Abeona enrolls first subject in Spain in ongoing phase 1/2 clinical trial in MPS IIIA, also known as Sanfilippo syndrome.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, has enrolled the first patient in its ABO-102 Phase 1/2 clinical trial in Spain in the fight against Mucopolysaccharidosis type III (MPS IIIA), more commonly known as Sanfilippo syndrome. The patient was enrolled at the Hospital Clinico Universitario of Santiago de Compostela.

Abeona has established a local subsidiary to manage clinical trial and regulatory development efforts in Europe.

Sanfilippo syndrome is a progressive disorder that primarily affects the brain and spinal cord, along with other body systems, according to the National Institutes of Health (NIH). People with MPS III generally do not display any features of the condition at birth, but they begin to show signs and symptoms of the disorder during early childhood. Affected children often initially have delayed speech and behavior problems.

NIH says those afflicted may become restless, destructive, anxious, or aggressive, and some display features of autism spectrum disorder, which is a condition characterized by difficulty with social interactions and communication. In later stages,  people with MPS III may develop seizures and movement disorders.

“Developing a local company presence in Spain allows us to exercise closer supervision and further advance Abeona’s gene therapy programs in Europe, as well as advance our relationships with the patient community,” Juan Ruiz, M.D., Ph.D., chief medical officer of Abeona Therapeutics, said in a statement.

In the clinical trial subjects receive a single, intravenous injection of ABO-102 to deliver the AAV viral vector systemically throughout the body to introduce a corrective copy of the gene that underlies the cause of the MPS IIIA disease.

Subjects are evaluated at multiple time points post-injection for safety assessments and signals of biopotency and clinical activity, which to date have demonstrated that ABO-102 successfully reaches target tissues throughout the body, including the central nervous system.

A total of nine subjects have been infused in the ongoing global MPS IIIA dose-escalation clinical trial, which has been well-tolerated through more than 2,000 cumulative follow-up days. Safety and efficacy data has been reviewed and enrollment in Cohort 3 continues at all three active clinical sites (U.S., Spain, and Australia).

(Source: Abeona Therapeutics Inc.)


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE